![origenis_logo_Pantone [Konvertiert]_2020](https://static.wixstatic.com/media/9afeac_83ea95f8f63144538d48a310b96d7f33~mv2.png/v1/fill/w_260,h_53,al_c,usm_0.66_1.00_0.01/origenis_logo_Pantone%20%5BKonvertiert%5D_2020.png){kind=logo}
Origenis Presents at Sportfire Conference
May 16, 2006
Origenis presents its proprietary multiparametric process for Drug Design, Synthesis and Characterisation at the Sportfire User Conference.
Aktuelle Beiträge
Alle ansehenSeptember 03, 2019 Mithilfe ihrer KI-basierten Small Molecules Technologie schafften es Michael Almstetter und seine zwei Mitstreiter ihre eigene Firma aufzubauen. Nun stand der nächste Schritt an: Do
June 04, 2019 Origenis AI Discovery Platform to Identify and Optimize Small Molecule Preclinical Development Candidates for Glioblastoma June 4, 2019 – Origenis GmbH, a privately-held German biopharma
May 16, 2019 Michael Almstetter, CEO Origenis GmbH, explained what can be learned from progress in oncology in order to develop new treatments for Alzheimer’s and Parkinson’s disease.